Drug-induced autoimmune thyroiditis during lorlatinib treatment in a patient with ALK-positive non-small cell lung cancer.

Lorlatinib has demonstrated significant efficacy for treating anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC); however, its safety profile-particularly regarding immune-related adverse events-remains incompletely characterized. We describe a case of ALK-positive NSCLC complicated by autoimmune thyroiditis during lorlatinib therapy. The temporal link between lorlatinib exposure, the emergence of thyroid autoantibodies, and their resolution following drug withdrawal raises the possibility that lorlatinib may influence autoimmune responses.